Zentrela

AIHamilton, ON

Hamilton neurotechnology company selling Cognalyzer, an AI-powered EEG platform that quantifies how consumer products change mental state for cannabis, caffeine, nootropic and wearable brands.

The Toronto skyline and the CN Tower at sunset, seen across Lake Ontario.

Canadian innovation builds a brighter tomorrow.

About

Company site: zentrela.com

Hamilton neurotechnology company selling Cognalyzer, an AI-powered EEG platform that quantifies how consumer products change mental state for cannabis, caffeine, nootropic and wearable brands.

  • Federal corporation Zentrela Inc. (Juri ID 940878-9), status Active, registered office in Hamilton, Ontario, incorporated 2015-08-17. ised-isde.canada.ca

  • Cognalyzer® AI is built on what the company describes as the world's largest continuously growing EEG database linked to characterized mental states, and reports 70+ partnerships and studies. zentrela.com

  • KGK Science was contracted to run a Phase II trial of the Cognalyzer on 150 participants after feasibility results won $1 million in Ontario Centre of Excellence funding (February 2025). kgkscience.com

  • Raised an $850K seed funding round, announced 2021-02-11. theforge.mcmaster.ca

Products & Services

Company site: zentrela.com

Products Zentrela publishes on its own site. Each card links to the page it was taken from.

Cognalyzer

AI-powered EEG platform

Company describes an AI-powered EEG platform that translates brain signals into measurable, quantified mental-state metrics for product-effect research, used by cannabis, caffeine, nootropic, OTC and wearable-device companies.

Learn more Source

Funding & Investors

Announced rounds only, newest first. Undisclosed amounts are shown as undisclosed.

  1. Seed

    Feb 11, 2021

Total disclosed: C$850.0KLatest: Seed · Feb 11, 2021

Partnerships

Publicly announced partnerships.

KGK Science

Contract research organization running the Ontario government-funded Phase II clinical trial of the Cognalyzer cannabis-impairment device on 150 participants.

Government & Grants

Government support actually received. Unpublished amounts are left out.

  1. Ontario Centre of Excellence — Cognalyzer Phase II cannabis-impairment testing

Recent News

  1. Feb 10, 2025Government

    KGK Science partners with Zentrela to test Ontario government-funded cannabis impairment device

    KGK Science announced a Phase II clinical trial of Zentrela's Cognalyzer EEG-based cannabis-impairment device on 150 regular THC users, following Ontario government funding after earlier feasibility results.

People

Sourced from the company's own pages or announcements.

Israel Gasperin

Founder

Technology Focus

Company site: zentrela.com

Terms the company uses about its own work.

EEGNeurotechnologyMachine learningProduct-effect research

Similar Companies

Other companies in AI.

Join Canada’s innovation community.

Discover companies, track funding, explore career opportunities and stay informed about Canada’s growing tech ecosystem.

624
Verified Companies
45
Funding Opportunities
19
Sectors
A stronger Canada together